NL-OMON30712已完成不适用
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CG5503 Immediate-Release Capsule in Healthy Elderly and Young Subjects - CG5503 IR pharmocokinetics in young and elderly
Johnson & Johnson Pharmaceutical0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •female (surgically sterilized or post-menopausal for at least two years or use for this study an acceptable method of birth control)
- •age 18-45 years
- •age 65 years and older
- •BMI is between 20 - 30 kg/m2 with a weight of not less than 50 kg
- •no smoking or you not smoking more than 10 cigarettes/day
- •Kidney function: for elderly CLCR > 60 mL/min; for young subjects CLCR at least 80 mL/min
排除标准
- •Important medical disorder, e.g., hepatitis B, cancer or HIV/AIDS.
- •Participation in another drug study within 60 days before the start of this study.
- •Blood donation within the 90 days prior to the start of this study or sudden blood loss of similar amount of blood.
研究者
相似试验
未知
1 期
An open-label, single-dose study to evaluate the pharmacokinetics and safety of DS-8500a in Japanese subjects with varying degrees of hepatic or renal functioSubjects with hepatic or renal impairmentJPRN-jRCT2080223081DAIICHI SANKYO CO., LTD.48
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LTBasilea Pharmaceutica International Ltd.45
进行中（未招募）
不适用
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic FibrosisCystic fibrosisEUCTR2015-001225-16-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development L.L.C22
进行中（未招募）
1 期
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age Protocol DORI-PED-1003; Phase 1hospitalized but medically stable infants (term and preterm), <12 weeks CA, who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics.MedDRA version: 12.0 Level: LLT Classification code 10004044 Term: Bacterial infection NOSEUCTR2009-014387-20-GBJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium52
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LVBasilea Pharmaceutica International Ltd.45